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DELAYED INFUSION OF ALLOANERGIZED DONOR PERIPHERAL BLOOD
MONONUCLEAR CELLS (PBMC) AUGMENTS PATHOGEN-SPECIFIC IM-
MUNE RECONSTITUTION AFTER T CELL DEPLETED (TCD) HAPLOIDENT-
ICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR
HIGH-RISK ACUTE LEUKEMIA/MDS
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Adoptive transfer of alloanergized donor T cells is a simple ap-
proach to augment immune reconstitution while limiting GvHD af-
ter TCD haploidentical (haplo) HSCT. However the optimal dose
and impact on antigen-specific immune reconstitution remain un-
known. On a new study, 7 adults and 4 children received fractionated
TBI (12Gy, n 5 5) or melphalan (140mg/m2, n 5 6), fludarabine,
thiotepa and ATG followed by CD34-selected peripheral blood
stem cells (median 9.4 CD341 and 0.02 CD31 106 cells/kg) from
haplo donors without further GvHD prophylaxis. All engrafted rap-
idly with full donor chimerism. Using an adaptive trial design, 10 pts
received alloanergized donor PBMC (generated by co-culture with
irradiated stimulator PBMC and humanized anti-B7.1 and -B7.2 an-
tibodies resulting in a median 6-fold reduction in alloresponses) in
escalating dose (Ds) cohorts: Ds1, 103 CD31 cells/kg (n 5 4), Ds2
104/kg (n5 3) and Ds3 105/kg (n5 3). 3 pts developed Gr 2–4 acute
GvHD, (1 Ds 2, 2 Ds3), all responding to treatment. 0/7 evaluable
pts developed chronic GvHD. 7/11 pts are alive (median f/u 8
months). 3 pts died from regimen related toxicity before D1100
and 1 from post-operative bleeding (D1738). 2 pts relapsed. CD4
T cell recovery was faster and functional pathogen-specific CD4
and CD8 T cells became detectable earlier in pts receiving higher
doses of alloanergized PBMC. Median time to CD4 ct .100/ml
was 9, 3 and 2 months and CMV or VZV-specific IFN-g1 T cells
became detectable at 7.5, 3 and 2.5 months at Ds 1,2 and 3 respec-
tively. The effector memory phenotype of recovering T cells was
consistent with peripheral expansion of infused alloanergized donor
T cells. 5 pts reactivated CMV before alloanergized PBMC infusion,
but no new episodes of CMV reactivation or CMV disease occurred
after infusion. 2 pts had large expansions of CMV-specific CD4 and
CD8 T cells (up to 10%) before D1100, coinciding with clearance
of CMV viremia. One Ds3 pt had adenoviremia despite high dose ci-
dofovir, resolving with expansion of infused donor T cells. 2 Ds1 pts
developed late viral infections: 1 reactivated EBV, and 1 developed
disseminated VZV resolving after VZV-specific T cells became de-
tectable. No late viral infections occurred in assessable Ds2/3 pts.
These early data support a contribution of alloanergized donor
PBMC to quantitative and qualitative immune reconstitution after
TCD haploHSCT. Further recruitment will determine the optimal
dose that can be safely administered in this setting.388
RAPID LYMPHOCYTE RECOVERY AND INTRAVENOUS IMMUNOGLOBU-
LIN INDEPENDENCE IN CHILDREN WITH SEVERE COMBINED IMMUNO-
DEFICIENCY (SCID) UNDERGOING ALLOGENEIC STEM CELL
TRANSPLANTATION WITH REDUCED INTENSITY CONDITIONING (RIC)
Guarino, J.A., Kletzel, M., Schneiderman, J., Jacobsohn, D.,
Chaudhury, S., Duerst, R., Tse,W. Children’s Memorial Hospital, North-
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Allogeneic SCT is curative for patients with SCID. We evaluated
aRICSCTapproach in thesepatients for engraftment, toxicityand im-
mune reconstitution. Between 2000 and 2008,RIC transplantwas per-
formed in 14 SCID patients (8 males and 6 females; median age 5
months (range 1.1–98.3)). Median time from diagnosis to transplant
was 1.8 months (range 1.0–96.3). Donor sources included: HLA-
matched related donor peripheral blood stemcells (PBSC) (n5 1), un-
related donor PBSC (7), related cord blood (CB) (1) and unrelated CB
(6). The median cell dose was 10.3  108 TNC/kg and 9.2  106
CD341cells/kg, and 2.0  108 TNC/kg and 1.5  106
CD341cells/kg for the PBSC and CB groups, respectively. RIC regi-
men includedFludarabine 30mg/m2/day, days -10 through -5, intrave-nous Busulfan targeted to AUC 4000–5000 microMol*min/day, days
-5 and -4, and anti-thymocyte globulin 2mg/kg/day, days -4 through
-1. GVHD prophylaxis included cyclosporine A and mycophenolate
mofetil. Engraftment occurred in 8/8 (100%) PBSC recipients and
4/6 (67%) CB recipients. Absolute neutrophil count (ANC) .1000
was achieved at a median of 17 days (range 4–26) and platelets.50K
was achieved at amedian of 23 days (12–90). The ANCnever dropped
\500 for 8/14 (57%), and platelets never dropped\20K for 8/14
(57%) patients. Full donor chimerism (VNTR$ 95%) was achieved
by a median of 26 days in 11/14 patients (79%; 8 received PBSC, 3 re-
ceived CB). Stable mixed donor chimerism (VNTR $ 50%) was
achieved by 74 days for 1 patient who received CB. Two patients
who received CB doses of 1.19/1.99  108 TNC/kg, and 0.69/0.55
 106 CD341cells/kg, respectively, experienced graft failure and
died from complications. The other patients tolerated the transplant
with mild toxicities. No VOD or grade III/IV acute or chronic
GVHD was seen. Infections seen post-transplant (bacterial (n 5 9),
candidemia (1), and viral (8)) responded to antimicrobial therapy ex-
cept in 1 graft failure patient. Immune reconstitution studies per-
formed post-transplant showed rapid recovery of various lymphocyte
subsets (table). Normal endogenous IgG levels were achieved by day
1180 and patients no longer required IV immunoglobulin. The
100-day transplant mortality was 14.3%. The Kaplan-Meier estimate
of overall survival at 2 years was 80% (95% CI 47.5–90%). This RIC
SCT protocol is a novel, non-toxic approach that allows for adequate
donor engraftmentwithearly immune reconstitution andcorrectionof
the underlying immunodeficiency in children with SCID.
Immune Reconstitution Post-RIC SCT *
Pre-SCT Day 1100 Day 1180 Day 1270 Day 1365(n514) (n511) (n511) (n511) (n57) p value**Absolute
Lymphocyte
Count
(NL.2500)2302 6 654 2645 6 630 3902 6 573 5628 6 1003 6978 6 788 0.0005CD41
(NL.1000)
499 6 379 415 6 95 806 6 181 1813 6 283 2523 6 441 0.0001CD81
(NL.800)
81 6 51 597 6 182 961 6 300 1571 6 515 1652 6 290 0.0001CD191
(NL.600)
1494 6 461 985 6 320 1078 6 218 1272 6 249 1543 6 218 0.55CD161CD561
(NL.200)
249 6 110 535 6 142 901 6 190 842 6 204 911 6 165 0.002Endogenous IgG
(NL$500)
415 6 95 N/A*** 933 6 198 828 6 223 654 6 175 0.03*All values are reported as mean 6 SEM. Cell counts are expressed in
cells/mm3 and IgG in mg/dl. NL5normal value.
**Statistical significance of differences by non-parametric ANOVA using
the Kruskal-Wallis test.
***Patients received IV immunoglobulin during the first 100 days post-
transplant.389
NK CELL RECONSTITUTION AFTER ALLOGENEIC TRANSPLANTATION
FROM UNRELATED DONORS USING CD3/CD19 DEPLETED GRAFT
Diaz, M.A., Gonzalez Vicent, M., Perez, A., Sevilla, J., Abad, L.,
Ramirez, M. Hospital Nin˜o Jesus, Madrid, Spain
We analyzed immune recovery after allogeneic PBSC transplanta-
tion from unrelated donors using CD3/CD19 depleted graft. Between
June 2005 and June 2008, thirteen pediatric patients (9 males and 4 fe-
males) aged between 1 and 16 years (median 5 years) diagnosed of leu-
kemiawere included.Tenpatientswere in1stCRand three in2ndCR.A
fludarabine-RICwasused.GraftsweremanipulatedbyCD3/CD19de-
pletion usingCliniMACSCell Separation System.Graft composition
was as follows: CD341; 11.0 106/kg (range; 5.66- 62.77),CD31; 0.5
 105/kg (range; 0.1–2.07) and CD561; 44.45  106/kg (range; 17.0–
149.82).Resultswere compared to a groupof pediatric patients (n5 13)
with leukemia conditioned with the same RIC and grafted with
aCD341 selectedPBSCfromunrelateddonors.Therewerenotdiffer-
ences inT andB lymphocyte recovery between groups.However, a sig-
nificantly difference was observed in the NK cell reconstitution. NK
